Predictors, Incidence, and Outcomes of Patients Undergoing Transfemoral Transcatheter Aortic Valve Implantation Complicated by Stroke.


Journal

Circulation. Cardiovascular interventions
ISSN: 1941-7632
Titre abrégé: Circ Cardiovasc Interv
Pays: United States
ID NLM: 101499602

Informations de publication

Date de publication:
03 2019
Historique:
entrez: 16 3 2019
pubmed: 16 3 2019
medline: 24 3 2020
Statut: ppublish

Résumé

Stroke remains one of the most devastating complications of transcatheter aortic valve implantation (TAVI). The aim of this study was to identify the incidence, timing, temporal trends, and predictors of stroke after TAVI and evaluate the outcomes of patients with stroke. The CENTER-Collaboration is an international collaboration consisting of 3 national registries and 7 local registries or prospective clinical trials, selected through a systematic review. Accordingly, a total of 10 982 patients undergoing transfemoral TAVI between 2007 and 2018 were included in the current patient-level pooled analyses. A total of 261 patients (2.4%) experienced stroke during the first month after TAVI. The median time between TAVI and stroke was 1 day (interquartile range, 0-6 days). The stroke rate was comparable in procedures performed in the early years of TAVI (2007-2012) to those in the more recent years of TAVI (2013-2018; both 2.4%; P=1.0). Independent predictors of stroke at 30 days were a history of cerebrovascular events (odds ratio, 2.2; 95% CI, 1.4-3.6; P=0.0012) and a glomerular filtration rate of <30 mL/min per 1.73 m In this large, global, patient-level analysis, the incidence of stroke after transfemoral TAVI was 2.4%. Prior cerebrovascular events and a low glomerular filtration rate independently predicted the occurrence of stroke after TAVI. The occurrence of stroke after TAVI was associated with a strikingly 6-fold increase of 30-day mortality; additionally, there was a 5-fold higher rate of new-onset atrial fibrillation in patients with stroke. URL: https://www.clinicaltrials.gov . Unique identifier: NCT03588247.

Sections du résumé

BACKGROUND
Stroke remains one of the most devastating complications of transcatheter aortic valve implantation (TAVI). The aim of this study was to identify the incidence, timing, temporal trends, and predictors of stroke after TAVI and evaluate the outcomes of patients with stroke.
METHODS AND RESULTS
The CENTER-Collaboration is an international collaboration consisting of 3 national registries and 7 local registries or prospective clinical trials, selected through a systematic review. Accordingly, a total of 10 982 patients undergoing transfemoral TAVI between 2007 and 2018 were included in the current patient-level pooled analyses. A total of 261 patients (2.4%) experienced stroke during the first month after TAVI. The median time between TAVI and stroke was 1 day (interquartile range, 0-6 days). The stroke rate was comparable in procedures performed in the early years of TAVI (2007-2012) to those in the more recent years of TAVI (2013-2018; both 2.4%; P=1.0). Independent predictors of stroke at 30 days were a history of cerebrovascular events (odds ratio, 2.2; 95% CI, 1.4-3.6; P=0.0012) and a glomerular filtration rate of <30 mL/min per 1.73 m
CONCLUSIONS
In this large, global, patient-level analysis, the incidence of stroke after transfemoral TAVI was 2.4%. Prior cerebrovascular events and a low glomerular filtration rate independently predicted the occurrence of stroke after TAVI. The occurrence of stroke after TAVI was associated with a strikingly 6-fold increase of 30-day mortality; additionally, there was a 5-fold higher rate of new-onset atrial fibrillation in patients with stroke.
CLINICAL TRIAL REGISTRATION
URL: https://www.clinicaltrials.gov . Unique identifier: NCT03588247.

Identifiants

pubmed: 30871358
doi: 10.1161/CIRCINTERVENTIONS.118.007546
doi:

Banques de données

ClinicalTrials.gov
['NCT03588247']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e007546

Auteurs

Wieneke Vlastra (W)

Heart Center, Amsterdam, the Netherlands (W.V., J.C., J.B., J.G.P.T., J.J.P., R.D.).
Department of Clinical and Experimental Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands (W.V., J.C., J.B., J.G.P.T., J.J.P., R.D.).

Pilar Jimenez-Quevedo (P)

Cardiovascular Institute, San Carlos University Hospital, Madrid, Spain (P.J.-Q.).

Didier Tchétché (D)

Clinique Pasteur, Toulouse, France (D.T., N.D.).

Jaya Chandrasekhar (J)

Heart Center, Amsterdam, the Netherlands (W.V., J.C., J.B., J.G.P.T., J.J.P., R.D.).
Department of Clinical and Experimental Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands (W.V., J.C., J.B., J.G.P.T., J.J.P., R.D.).
The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY (J.C., S.S., G.D., R.M.).

Fabio S de Brito (FS)

Heart Institute (InCor), University of São Paulo Medical School, Brazil (F.S.d.B.).

Marco Barbanti (M)

Division of Cardiology, Policlinico-Vittorio Emanuele Hospital, University of Catania, Italy (M.B.).

Ran Kornowski (R)

Cardiology Department, Rabin Medical Center, Petach Tikva, Israel (R.K., K.O.).

Azeem Latib (A)

Interventional Cardiology Unit, San Raffaele Scientific Institute, Milan, Italy (A.L., M.P.).

Augusto D'Onofrio (A)

Interventional Cardiology Unit, Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Italy (A.D., G.T.).

Flavio Ribichini (F)

Division of Cardiology, Department of Medicine, University of Verona, Italy (F.R., M.L.).

Jan Baan (J)

Heart Center, Amsterdam, the Netherlands (W.V., J.C., J.B., J.G.P.T., J.J.P., R.D.).
Department of Clinical and Experimental Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands (W.V., J.C., J.B., J.G.P.T., J.J.P., R.D.).

Jan G P Tijssen (JGP)

Heart Center, Amsterdam, the Netherlands (W.V., J.C., J.B., J.G.P.T., J.J.P., R.D.).
Department of Clinical and Experimental Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands (W.V., J.C., J.B., J.G.P.T., J.J.P., R.D.).

Jose M De la Torre Hernandez (JM)

Hospital Marqués de Valdecilla, Servicio de Cardiología, Santander, Cantabria, Spain (J.M.D.l.T.H.).

Nicolas Dumonteil (N)

Clinique Pasteur, Toulouse, France (D.T., N.D.).

Rogério Sarmento-Leite (R)

Instituto de Cardiologia do Rio Grando do Sul, Brazil (R.S.-L.).

Samantha Sartori (S)

The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY (J.C., S.S., G.D., R.M.).

S Rosato (S)

National Centre for Global Helath, Istituto Superiore di Sanità, Rome, Italy (S.R.).

Giuseppe Tarantini (G)

Interventional Cardiology Unit, Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Italy (A.D., G.T.).

Mattia Lunardi (M)

Division of Cardiology, Department of Medicine, University of Verona, Italy (F.R., M.L.).

Katia Orvin (K)

Cardiology Department, Rabin Medical Center, Petach Tikva, Israel (R.K., K.O.).

Matteo Pagnesi (M)

Interventional Cardiology Unit, San Raffaele Scientific Institute, Milan, Italy (A.L., M.P.).

Rosana Hernandez-Antolin (R)

Department of Cardiology, University Hospital Ramon y Cajal, Madrid, Spain (R.H.-A.).

Thomas Modine (T)

Centre Hospitalier Universitaire, Lille, France (T.M.).

George Dangas (G)

The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY (J.C., S.S., G.D., R.M.).

Roxana Mehran (R)

The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY (J.C., S.S., G.D., R.M.).

Jan J Piek (JJ)

Heart Center, Amsterdam, the Netherlands (W.V., J.C., J.B., J.G.P.T., J.J.P., R.D.).
Department of Clinical and Experimental Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands (W.V., J.C., J.B., J.G.P.T., J.J.P., R.D.).

Ronak Delewi (R)

Heart Center, Amsterdam, the Netherlands (W.V., J.C., J.B., J.G.P.T., J.J.P., R.D.).
Department of Clinical and Experimental Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands (W.V., J.C., J.B., J.G.P.T., J.J.P., R.D.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH